Show simple item record

dc.contributor.authorWalsh, Naomi
dc.contributor.authorLarkin, Annemarie
dc.contributor.authorKennedy, Susan
dc.contributor.authorConnolly, Lisa
dc.contributor.authorBallot, Jo
dc.contributor.authorOoi, Wei
dc.contributor.authorGullo, Giuseppe
dc.contributor.authorCrown, John
dc.contributor.authorClynes, Martin
dc.contributor.authorO'Driscoll, Lorraine
dc.date.accessioned2010-03-12T15:43:02Z
dc.date.available2010-03-12T15:43:02Z
dc.date.issued2009
dc.identifier.citationExpression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma. 2009, 9:6 BMC Urolen
dc.identifier.issn1471-2490
dc.identifier.pmid19552816
dc.identifier.doi10.1186/1471-2490-9-6
dc.identifier.urihttp://hdl.handle.net/10147/94205
dc.description.abstractBACKGROUND: Renal cell carcinoma patients respond poorly to conventional chemotherapy, this unresponsiveness may be attributable to multidrug resistance (MDR). The mechanisms of MDR in renal cancer are not fully understood and the specific contribution of ABC transporter proteins which have been implicated in the chemoresistance of various cancers has not been fully defined in this disease. METHODS: In this retrospective study the expression of two of these transporter efflux pumps, namely MDR-1 P-gp (ABCB1) and MRP-1 (ABCC1) were studied by immunohistochemistry in archival material from 95 renal cell carcinoma patients. RESULTS: In the first study investigating MDR-1 P-gp and MRP-1 protein expression patterns in renal cell carcinoma patients, high levels of expression of both efflux pumps are observed with 100% of tumours studied showing MDR-1 P-gp and MRP-1 positivity. CONCLUSION: Although these findings do not prove a causal role, the high frequency of tumours expressing these efflux pumps suggests that they may be important contributors to the chemoresistance of this tumour type.
dc.language.isoenen
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAntineoplastic Agents
dc.subject.meshCarcinoma, Renal Cell
dc.subject.meshFemale
dc.subject.meshGene Expression Regulation, Neoplastic
dc.subject.meshHumans
dc.subject.meshKidney Neoplasms
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshMultidrug Resistance-Associated Proteins
dc.subject.meshNeoplasm Proteins
dc.subject.meshP-Glycoprotein
dc.subject.meshTumor Cells, Cultured
dc.subject.meshTumor Markers, Biological
dc.titleExpression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma.en
dc.contributor.departmentNational Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland. naomi.walsh@dcu.ieen
dc.identifier.journalBMC urologyen
refterms.dateFOA2018-09-03T10:38:51Z
html.description.abstractBACKGROUND: Renal cell carcinoma patients respond poorly to conventional chemotherapy, this unresponsiveness may be attributable to multidrug resistance (MDR). The mechanisms of MDR in renal cancer are not fully understood and the specific contribution of ABC transporter proteins which have been implicated in the chemoresistance of various cancers has not been fully defined in this disease. METHODS: In this retrospective study the expression of two of these transporter efflux pumps, namely MDR-1 P-gp (ABCB1) and MRP-1 (ABCC1) were studied by immunohistochemistry in archival material from 95 renal cell carcinoma patients. RESULTS: In the first study investigating MDR-1 P-gp and MRP-1 protein expression patterns in renal cell carcinoma patients, high levels of expression of both efflux pumps are observed with 100% of tumours studied showing MDR-1 P-gp and MRP-1 positivity. CONCLUSION: Although these findings do not prove a causal role, the high frequency of tumours expressing these efflux pumps suggests that they may be important contributors to the chemoresistance of this tumour type.


Files in this item

Thumbnail
Name:
19552816.pdf
Size:
392.9Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record